Duke University

Verily, Duke and Stanford launch Project Baseline study

Thursday, April 20, 2017

Verily Life Sciences, an Alphabet company, in partnership with Duke University School of Medicine and Stanford Medicine, announced the initiation of the Project Baseline study, a longitudinal study that will collect broad phenotypic health data from approximately 10,000 participants, who will each be followed over the course of at least four years. The study is the first initiative of Project Baseline, a broader effort designed to develop a well-defined reference, or “baseline,” of health as well as a rich data platform that may be used to better understand the transition from health to disease and identify additional risk factors for disease. Beyond this initial study, Project Baseline endeavors to test and develop new tools and technologies to access, organize and activate health information.

[Read More]

GeoVax forms scientific advisory board

Tuesday, January 3, 2017

GeoVax Labs, a biotechnology company specializing in developing human vaccines, has announced the formation of its inaugural Scientific Advisory Board (SAB) to provide expert guidance as the company advances its vaccine development for multiple targets including HIV, hemorrhagic fever (Ebola, Sudan, Marburg, Lassa), Zika virus, chronic Hepatitis B and immuno-oncology.

[Read More]

Ebola-affected countries receive NIH support research training support

Monday, October 31, 2016

The recent Ebola epidemic in West Africa highlighted the need for better global preparedness and response to disease outbreaks. To help address that need in Guinea, Liberia and Sierra Leone—the countries most affected by the epidemic—the NIH has established a new program to strengthen the research capacity to study Ebola, Lassa fever, yellow fever and other emerging viral diseases. In the initiative’s first funding round, NIH’s Fogarty International Center is awarding grants to four U.S. institutions that will partner with West African academic centers to design training programs for their scientists and health researchers.

[Read More]

Boehringer, Duke collaborate on IPF patient registry

Friday, August 26, 2016

Boehringer Ingelheim Pharmaceuticals and the Duke Clinical Research Institute (DCRI) have announced the expansion of the Idiopathic Pulmonary Fibrosis—PROspective Outcomes (IPF-PRO) Registry, a patient registry developed to uncover insights into IPF, a rare and serious lung disease. The expansion will increase the study enrollment from 300 patients at 18 study sites to 1,500 patients at approximately 45 sites, creating the largest registry of newly diagnosed IPF patients.

[Read More]

Sunovion releases long-term data of biopolar depression treatment Latuda

Monday, May 23, 2016

Sunovion Pharmaceuticals has published results in the journal Depression and Anxiety from a six-month, open-label extension study that evaluated the long-term safety, tolerability and effectiveness of Latuda (lurasidone HCI) when used either as monotherapy or as adjunctive therapy in combination with lithium or valproate in adults with major depressive episodes associated with bipolar I disorder (bipolar depression).

[Read More]